A departing CMO pens a sad farewell as he heads back to the UK biopharma scene
We’re seeing the C-suites of a whole group of biotech and pharma companies in flux this week as leadership groups evolve and top execs hunt bigger and better things for their careers. Most of this news is encapsulated in short, dry remarks reserved for SEC filings.
But the departing CMO at Theravance $TBPH, Brett Haumann, clearly wanted it widely known that he’s making a reluctant exit at the company after a 7-year stint. His 8-K this week notes he’s going to change scenes and move to the UK as much for family reasons as anything else. And the note quotes him directly.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.